The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Tenet Healthcare's Q2 results demonstrated strong growth driven by its Ambulatory segment, which successfully offset a decline in patient days. The company reported a 43.5% increase in non-GAAP EPS and subsequently raised its FY2026 guidance for revenue and free cash flow. Additionally, Tenet announced a $2 billion increase in its share repurchase authorization while maintaining a 'Strong Buy' rating from most market analysts.